EUVIMEDEUVIMED entdecken
Open Access

Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause

JoAnn V Pinkerton, James A Simon, Hadine Joffe, Pauline M Maki, Rossella E Nappi, Nick Panay, Claudio N Soares, Rebecca C Thurston, Cecilia Caetano, Claudia Haberland, Nazanin Haseli Mashhadi, Ulrike Krahn und 4 weitere

JAMA · 22.10.2024 · 332 (16) · 1343

DOI: 10.1001/jama.2024.14618 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 22.10.2024. Verfasst von JoAnn V Pinkerton und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Division Midlife Health, University of Virginia Health, Charlottesville. Die Arbeit wurde bisher 122-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Safe and effective nonhormonal treatments for menopausal vasomotor symptoms (VMS) are needed.

Objective

To evaluate the efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist, for the treatment of moderate to severe menopausal vasomotor symptoms. Design, Setting, and Participants Two randomized double-blind phase 3 trials (OASIS 1 and 2) included postmenopausal participants aged 40 to 65 years experiencing moderate to severe vasomotor symptoms (OASIS 1: 77 sites in the US, Europe, and Israel from August 27, 2021, to November 27, 2023, and OASIS 2: 77 sites in the US, Canada, and Europe from October 29, 2021, to October 10, 2023).

Intervention

Once daily oral elinzanetant, 120 mg, for 26 weeks or matching placebo for 12 weeks followed by elinzanetant, 120 mg, for 14 weeks. Main Outcomes and Measures Primary end points included mean change in frequency and severity of moderate to severe vasomotor symptoms from baseline to weeks 4 and 12, measured by the electronic hot flash daily diary. Secondary end points included Patient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b total T score and Menopause-Specific Quality of Life questionnaire total score from baseline to week 12.

Results

Eligible participants (mean [SD] age, OASIS 1: 54.6 [4.9] years; OASIS 2: 54.6 [4.8] years) were randomized to elinzanetant (OASIS 1: n = 199; OASIS 2: n = 200) or placebo (OASIS 1: n = 197; OASIS 2: n = 200). A total of 309 (78.0%) and 324 (81.0%) completed OASIS 1 and 2, respectively. For the elinzanetant and placebo groups, the baseline mean (SD) VMS per 24 hours were 13.4 (6.6) vs 14.3 (13.9) (OASIS 1) and 14.7 (11.1) v 16.2 (11.2) (OASIS 2). Baseline VMS severity was 2.6 (0.2) vs 2.5 (0.2) (OASIS 1) and 2.5 (0.2) vs 2.5 (0.2) (OASIS 2). Elinzanetant significantly reduced VMS frequency vs placebo at week 4 (OASIS 1: −3.3 [95% CI, −4.5 to −2.1], P < .001; OASIS 2: −3.0 [95% CI, −4.4 to −1.7], P < .001) and at week 12 (OASIS 1: −3.2 [95% CI, −4.8 to −1.6], P < .001; OASIS 2: −3.2 [95% CI, −4.6 to −1.9], P < .001). Elinzanetant also improved VMS severity vs placebo at week 4 (OASIS 1: −0.3 [95% CI, −0.4 to −0.2], P < .001; OASIS 2: −0.2 [95 CI, −0.3 to −0.1], P < .001) and week 12 (OASIS 1: −0.4 [95% CI, −0.5 to −0.3], P < .001; OASIS 2: −0.3 [95% CI, −0.4 to −0.1], P < .001). Elinzanetant improved sleep disturbances and menopause-related quality of life at week 12, and the safety profile was favorable. Conclusions and Relevance Elinzanetant was well tolerated and efficacious for moderate to severe menopausal VMS. Trial Registration ClinicalTrials.gov Identifier: OASIS 1: NCT05042362 , OASIS 2: NCT05099159

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Division Midlife Health, University of Virginia Health, Charlottesville.
  • IntimMedicine Specialists, George Washington University, Washington, DC.
  • Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Department of Psychiatry, Psychology, and OB/GYN, University of Illinois at Chicago.
  • Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, Pavia, Italy.
  • Research Center for Reproductive Medicine, Gynecological Endocrinology, and Menopause, IRCCS San Matteo Foundation, Pavia, Italy.

Zitieren

APA

Pinkerton, J. V., Simon, J. A., Joffe, H., Maki, P. M., Nappi, R. E., Panay, N., Soares, C. N., Thurston, R. C., Caetano, C., Haberland, C., Haseli Mashhadi, N., Krahn, U., Mellinger, U., Parke, S., Seitz, C., & Zuurman, L. (2024). Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause. JAMA, 332(16), 1343. https://doi.org/10.1001/jama.2024.14618

Vancouver

Pinkerton JV, Simon JA, Joffe H, Maki PM, Nappi RE, Panay N, et al. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause. JAMA. 2024;332(16):1343. doi:10.1001/jama.2024.14618

BibTeX
@article{Pinkerton2024,
  author = {Pinkerton, JoAnn V and Simon, James A and Joffe, Hadine and Maki, Pauline M and Nappi, Rossella E and Panay, Nick and Soares, Claudio N and Thurston, Rebecca C and Caetano, Cecilia and Haberland, Claudia and Haseli Mashhadi, Nazanin and Krahn, Ulrike and Mellinger, Uwe and Parke, Susanne and Seitz, Christian and Zuurman, Lineke},
  title = {Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause},
  journal = {JAMA},
  year = {2024},
  volume = {332},
  number = {16},
  pages = {1343},
  doi = {10.1001/jama.2024.14618}
}
Kostenlos starten →